1
|
Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O, Grandchamp B. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. Urology 2015; 86:1185-90. [PMID: 26364695 DOI: 10.1016/j.urology.2015.07.036] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 06/15/2015] [Accepted: 07/09/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To assess the diagnostic and prognostic performance of a noninvasive FGFR3 mutation analysis. After transurethral resection (TUR) of noninvasive bladder transitional cell carcinoma (B-TCC), recurrence occurs in 70% of patients, thus justifying cystoscopic surveillance. MATERIALS AND METHODS A prospective multicenter study was carried out with a 2-year follow-up of patients with superficial B-TCC. Urine samples were collected before TUR and then before each cystoscopy during follow-up. Screening for the most prevalent FGFR3 mutations was done using urinary cells. The prognostic significance of an FGFR3 mutation at the time of the initial diagnosis was determined. The performance of the test in diagnosing and/or predicting recurrence during follow-up was assessed by calculating sensitivity and specificity. RESULTS Of 191 patients studied, 74 (39%) had a positive analysis before TUR (FGFR3 mutation group). The presence of an FGFR3 mutation at the time of diagnosis was associated with a shorter time to recurrence (P = .02). During follow-up, 68 patients from the FGFR3 mutation group were evaluated. FGFR3 mutation analysis showed a sensitivity of 0.73 and a specificity of 0.87 when compared with the results of cystoscopy. A positive urine test was predictive of recurrence either at the time of the positive result or later during the 2-year follow-up, with a sensitivity of 0.70 and a specificity of 0.87. CONCLUSION Among patients with an FGFR3 mutation in the initial tumor, a noninvasive urine test during follow-up can be valuable in diagnosing or predicting subsequent recurrence.
Collapse
Affiliation(s)
- Camille Couffignal
- INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Department of Biostatistics, Bichat Hospital, Paris, France
| | | | | | - Vincent Ravery
- AP-HP, Department of Urology, Bichat Hospital, Paris, France
| | - Idir Ouzaid
- AP-HP, Department of Urology, Bichat Hospital, Paris, France
| | - Morgan Roupret
- GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitié Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Pitié Hospital, Paris, France
| | - Véronique Phe
- AP-HP, Department of Urology, Pitié Hospital, Paris, France
| | - Calin Ciofu
- AP-HP, Department of Urology, Tenon Hospital, Paris, France
| | - Florence Tubach
- INSERM, ECEVE, UMR 1123, CIC-EC 11425, Paris, France; ECEVE, UMR 1123, University of Paris Diderot, Sorbonne Paris Cité, Paris, France; AP-HP, Department of Epidemiology and Clinical Research, Bichat Hospital, Paris, France
| | - France Mentre
- INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Department of Biostatistics, Bichat Hospital, Paris, France
| | - Olivier Cussenot
- GRC-05, University Institute of Cancerology (IUC), Departments of Urology Tenon and Pitié Hospitals, University Paris-6, Paris, France; AP-HP, Department of Urology, Tenon Hospital, Paris, France
| | | |
Collapse
|
3
|
Rosser CJ, Urquidi V, Goodison S. Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med 2013; 7:779-90. [DOI: 10.2217/bmm.13.73] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Early detection of bladder tumors is critical for improved patient outcomes. The standard method for detection and surveillance of bladder tumors is cystoscopy with urinary cytology. Limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. Ideally, such assays would be applicable to noninvasively obtained, voided urine, and be designed not only for diagnosis, but also for monitoring disease recurrence and response to therapy. Consequently, the development of a noninvasive urine-based assay would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine-based biomarkers reported in the literature. In addition, some new technologies that have been used to identify novel urinary biomarkers are highlighted.
Collapse
Affiliation(s)
- Charles J Rosser
- Department of Urology, University of Central Florida College of Medicine, Orlando, FL 32527, USA
- Nonagen Bioscience Corporation, Orlando, FL 32527, USA
| | - Virginia Urquidi
- Nonagen Bioscience Corporation, Orlando, FL 32527, USA
- Cancer Research Institute, MD Anderson Cancer Center Orlando, Orlando, FL 32527, USA
| | - Steve Goodison
- Nonagen Bioscience Corporation, Orlando, FL 32527, USA
- Cancer Research Institute, MD Anderson Cancer Center Orlando, Orlando, FL 32527, USA
| |
Collapse
|
4
|
Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, Lepage ML, Maille P, Renou A, Vordos D, Abbou CC, Bakkar A, Asselain B, Kourda N, El Gaaied A, Leroy K, Laplanche A, Benhamou S, Lebret T, Allory Y, Radvanyi F. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One 2012; 7:e48993. [PMID: 23272046 PMCID: PMC3521761 DOI: 10.1371/journal.pone.0048993] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2012] [Accepted: 10/03/2012] [Indexed: 11/18/2022] Open
Abstract
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18-0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28-0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23-1.36] (p = 0.12) and OR = 0.99 [0.37-2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage.
Collapse
Affiliation(s)
- Yann Neuzillet
- Department of Urology, Hôpital Foch, Université de Versailles – Saint-Quentin-en-Yvelines, Suresnes, France
- Centre de Recherche, Institut Curie, Paris, France
- UMR144, CNRS, Paris, France
| | - Xavier Paoletti
- Department of Biostatistics, Institut Curie, INSERM U900, Paris, France
| | - Slah Ouerhani
- Centre de Recherche, Institut Curie, Paris, France
- UMR144, CNRS, Paris, France
- Unité 855, INSERM, Créteil, France
- Faculté des Sciences de Tunis, Tunis, Tunisia
- Institut Pasteur, Tunis, Tunisia
| | - Pierre Mongiat-Artus
- Department of Urology, Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France
- INSERM U944, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France
| | - Hany Soliman
- INSERM U944, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France
- Department of Biochemistry, Hôpital Saint-Louis, APHP, Paris, France
| | - Hugues de The
- Department of Biochemistry, Hôpital Saint-Louis, APHP, Paris, France
- UMR7151, CNRS, Université Paris 7, Paris, France
| | | | - Yves Denoux
- Department of Pathology, Hôpital Foch, Suresnes, France
| | - Vincent Molinie
- Department of Pathology, Hôpital Saint-Joseph, Paris, France
| | - Aurélie Herault
- Centre de Recherche, Institut Curie, Paris, France
- UMR144, CNRS, Paris, France
| | - May-Linda Lepage
- Centre de Recherche, Institut Curie, Paris, France
- UMR144, CNRS, Paris, France
| | - Pascale Maille
- Department of Pathology, Hôpital Henri Mondor, APHP, Créteil, France
| | - Audrey Renou
- Department of Pathology, Hôpital Henri Mondor, APHP, Créteil, France
| | - Dimitri Vordos
- Department of Urology, Hôpital Henri Mondor, APHP, Créteil, France
| | - Claude-Clément Abbou
- Unité 855, INSERM, Créteil, France
- Department of Urology, Hôpital Henri Mondor, APHP, Créteil, France
| | | | - Bernard Asselain
- Department of Biostatistics, Institut Curie, INSERM U900, Paris, France
| | | | | | - Karen Leroy
- Department of Pathology, Hôpital Henri Mondor, APHP, Créteil, France
| | - Agnès Laplanche
- INSERM U794/CNRS FRE2939, Institut Gustave Roussy, Villejuif, France
| | - Simone Benhamou
- INSERM U794/CNRS FRE2939, Institut Gustave Roussy, Villejuif, France
| | - Thierry Lebret
- Department of Urology, Hôpital Foch, Université de Versailles – Saint-Quentin-en-Yvelines, Suresnes, France
| | - Yves Allory
- Unité 855, INSERM, Créteil, France
- Department of Pathology, Hôpital Henri Mondor, APHP, Créteil, France
| | - François Radvanyi
- Centre de Recherche, Institut Curie, Paris, France
- UMR144, CNRS, Paris, France
- * E-mail:
| |
Collapse
|
7
|
Abstract
Detailed molecular insights into bladder cancer biology might allow more detailed prognostication and optimization of treatment with the objective of improving patient outcome and quality of life. However, in bladder cancer research the search for biomarkers has been called into question and has even obtained notoriety. It is unlikely that any single marker will be able to improve prognostication for patients with bladder cancer above and beyond grade and stage, but a combination of multiple independent markers might more precisely predict the outcome. From a previous review, we identified seven biomarkers to study within the setting of the Bladder Cancer Prognosis Programme (BCPP), a 5-year multicentre programme of research based at the University of Birmingham and funded by Cancer Research UK, investigating their effectiveness in predicting recurrence and progression. As part of the ongoing quality-assurance process for BCPP we present an updated review of our selected biomarkers, as well as highlighting other recent important developments in bladder cancer research.
Collapse
Affiliation(s)
- Richard T Bryan
- Department of Public Health Epidemiology and Biostatistics, School of Population Sciences, University of Birmingham, Birmingham, UK.
| | | | | | | | | |
Collapse
|
9
|
Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008; 4:71-83. [PMID: 18241002 DOI: 10.2217/14796694.4.1.71] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Bladder cancer presents several challenges in clinical management. For the large group of noninvasive tumors, key problems are the development of multiple recurrences that require long-term surveillance and a lack of effective therapies to prevent recurrence. For the smaller group of poor prognosis patients with invasive disease, novel therapies are urgently needed. The identification of mutations of FGF receptor 3 (FGFR3) in most noninvasive bladder tumors and the recent finding of overexpression of this receptor not only in superficial tumors but also in many invasive bladder cancers has generated optimism that therapies targeting this receptor tyrosine kinase may have major application in the treatment of urothelial cancers. There is little information on the other members of this receptor family apart from FGFR2, which is implicated as a tumor suppressor. Recent preclinical evaluations of FGFR3 as a therapeutic target have provided a strong impetus for the development of targeted agents for clinical use.
Collapse
Affiliation(s)
- Margaret A Knowles
- Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
| |
Collapse
|